Denis V. Aleksantsev

Denis V. Aleksantsev

Auto-generated profile, based on publicly available information

Denis V. Aleksantsev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
AGA. S. Gorbunova
A. S. Gorbunova
DKD. V. Kuzmichev
D. V. Kuzmichev
ZMZ. Z. Mamedli
Z. Z. Mamedli
AAA. A. Aniskin
A. A. Aniskin
APA. V. Polinovsky
A. V. Polinovsky
AKA. V. Korshak
A. V. Korshak
The formation of intestinal stoma is performed during routine and emergency operations. This review provides a brief historical overview of the main stages of development of methods colo- and ileostomy. The article presents indications, as well as possible complications that may happen during operative treatment. It is occurred that there is little evidentiary material of colo- or ileostomy in evaluating complications that are associated with the various surgical methods of intestinal stoma formation. The purpose of this review is to summarize the current data on stoma formation and determine the method to use.

5 June 2023 in Koloproktologia
Verified
Journal Article
Open access
PDF file
ASA. Seidinovich
A. Seidinovich
SGS. S. Gordeev
S. S. Gordeev
AMA. A. Markovich
A. A. Markovich
IKI. G. Komarov
I. G. Komarov
ДАД. В. Алексанцев
Д. В. Алексанцев
ZMZ. Z. Mamedli
Z. Z. Mamedli
AIM: to evaluate the effectiveness of first-line chemotherapy in patients with colorectal neuroendocrine cancer (NEC).PATIENTS AND METHODS: a retrospective study included patients with metastatic colorectal NEC (2000-2020). The main analyzed parameter was the response rate to treatment according to the RECIST criteria, depending on the regimen used in the first line. The overall survival was additional parameter.RESULTS: the study included 27 patients (13 with initial stage IV disease and 14 with progression after primary radical treatment). Ten patients in the 1st line underwent chemotherapy according to the EP scheme, 4 — XELOX, 2 — FOLFIRI, 2 — Irinotecan and Cisplatin, 1 — Samarium, 1 — Nivolumab, 1 — 5-FU-LV. Most often, the treatment effect (partial response or stabilization) was observed against the background of chemotherapy according to the EP scheme — in 60% of patients. The median OS was 7 months.CONCLUSION: the use of chemotherapy according to the EP regimen is the preferred options for the treatment of metastatic colorectal NEC. The median OS in this group of patients remains extremely low, and new clinical trials are needed.

20 June 2026 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
DAD. V. Aleksantsev
D. V. Aleksantsev
АВАлексанцев Д. В.
Алексанцев Д. В.
SPS. S. Peregorodieva
S. S. Peregorodieva
ПСПерегородиева С. С.
Перегородиева С. С.
APA. V. Polynovskiy
A. V. Polynovskiy
ГСГордеев С. С.
Гордеев С. С.
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.

7 June 2024 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
DAD. V. Aleksantsev
D. V. Aleksantsev
ZMZ. Z. Mamedli
Z. Z. Mamedli
APA. V. Polinovsky
A. V. Polinovsky
UBU. N. Babadjanov
U. N. Babadjanov
KTKh. R. Temirsultanova
Kh. R. Temirsultanova
EME. A. Mustafazade
E. A. Mustafazade
Aim. To evaluate the frequency and clinical characteristics of positional neuropathies in patients with cancer who underwent surgery.Materials and methods. A retrospective study of medical records of patients undergoing surgical treatment in 2023, who showed signs of secondary neuropathy of the upper and/or lower extremities in the postoperative period. The main analyzed parameter was the frequency of postoperative neuropathies among patients who underwent surgery; additional parameters were the degree of neurological deficit according to the neurological deficit assessment scale, the median regression of neurological deficit. Results. The study included 29 patients who underwent surgery at the National Medical Research Center of Oncology named after N. N. Blokhin in 2023, who developed a clinical picture of positional neuropathy in the postoperative period. The overall incidence of positional neuropathies was 0.28 %. Neuropathies of the brachial plexus were predominant (96 %). A severe degree of neurological deficit was noted in 35 %, medium – in 45 %, mild – in 20 % of patients. 27.5 % of patients continued to have varying degrees of neurological deficit over a 10-month period.Conclusion. Positional neuropathies can persist for a long time; it is necessary to develop methods for their prevention.

20 March 2025 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
APA. V. Polynovsky
A. V. Polynovsky
DKD. V. Kuzmichev
D. V. Kuzmichev
ATAlexey Tryakin
Alexey Tryakin
MCM. V. Chernykh
M. V. Chernykh
OKO. A. Kuznetsova
O. A. Kuznetsova
ZMZ. Z. Mamedli
Z. Z. Mamedli
Background. The development of local recurrences and distant metastases make the problem of treating locally advanced rectal cancer one of the main problems in modern oncoproctology. The organ-preserving approach, sphincter-preserving operations, the role of a complete clinical response to therapy and the low compliance of patients with adjuvant treatment remain in the focus of attention of scientists.Aim. Evaluation of the effectiveness of neoadjuvant sequential induction chemotherapy (CT), chemoradiotherapy (CRT), and CapOx consolidating chemotherapy in patients with locally advanced rectal cancer.Methods. From December 2019 to June 2024, an open-label, randomized phase III study enrolled patients with locally advanced rectal cancer from 3 centers. The inclusion criteria for patients in the study were: histologically confirmed adenocarcinoma, lower and middle rectal cancer, magnetic resonance imaging on a Tesla 3 machine CRM+/4N0-2M0, age 18–75 years, ECOG performance status 0–1. Patients were divided into 2 groups: in the study group, treatment began with 2 courses of induction CT according to the CapOx regimen (oxaliplatin 130 mg/m2 on the 1st day of the course intravenously by drip, capecitabine 2000 mg/m2 twice a day at 12-hour intervals for 14 days, 7 days break). Then, a long course of chemoradiotherapy was carried out: 44 Gy to the areas of regional metastasis, 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. One to two weeks after the end of CRT, two more courses of consolidation CT were carried out according to the CapOx scheme. A control examination was performed 10–12 weeks after the end of CRT. In the control group, a prolonged course of CRT was carried out: ROD 2 Gy, SOD 44 Gy to the areas of regional metastasis and SOD 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. The primary endpoint was 3-year disease-free survival, calculated from the start of treatment to the date of progression and/or death from any cause or the date of last follow-up. Situations when a patient did not die and did not have disease progression were considered as censored events. Survival was calculated using the Kaplan–Meier method.Results. 247 patients were included in the study, 178 (72.1 %) underwent a complete course of treatment, 12 (4.9 %) patients are in the process of treatment or waiting for surgery, 25 (10.1 %) patients were excluded from the study for various reasons: organizational problems, refusal of treatment after randomization, detection of a synchronous tumor or metastases before starting treatment. The remaining 32 (12.9 %) patients did not follow the planned treatment protocol due to progression, death or refusal to continue treatment. The prevalence of acute grade III–V toxicities during preoperative treatment was 6.8 % in the CRT + CT group versus 4.7 % in the CRT group. 19 patients with a complete clinical response refused surgical treatment. 6 (5.8 %) patients in the CRT group and 13 (12.1 %) patients from the group in the CRT + CT group (p = 0.05). The disease free median duration of follow-up in group complete clinical response was 1086 days (36.2 months). Sphincter-sparing operations in the CRT + CT group were performed in 54 (65.8 %) patients versus 41 (53.2 %) in the CRT group (p = 0.05). A subgroup analysis of patients with low rectal cancer showed a significant increase in the frequency of sphincter preservation operations in the main group – 23 (46.9 %) versus 16 (31.4 %) in the control group (p = 0.05). On the basis of the Clavien–Dindo classification, the prevalence of surgical complications was similar between the two groups. The total rate of pCR in the CRT + CT group was 41.2 %, which was significantly higher than that in the CRT group (29.8 %). We demonstrated that patients receiving CRT with neoadjuvant CT were well tolerated, with a compliance rate of 71.2 % than those received adjuvant CT (31.2 %, p = 0.05). In particular, 95 % of the patients in the main group underwent 4 planned courses of neoadjuvant CT. 32.5 % of patients in the chemoradiotherapy group did not start adjuvant CT versus 16 % in the study group. The median duration of follow-up was 36 month. Locoregional recurrence was observed in 5 patients: 3 (2.8 %) in the CRT + CT group (1 patient was operated in a non-specialized clinic, after completion of preoperative treatment within the protocol) and 2 (1.9 %) in the CRT group. There was no significant difference in distant metastases: 20 (19.2 %) patients in CRT group and 21 (19.6 %) patients in the study group. There was no significant difference in dieseas-free survival (75 % in the CRT group versus 77 % in the CRT + CT group). Conclusion. Chemoradiotherapy with preoperative CT followed by surgery was efficacious for locally advanced rectal cancer with a significant increase frequency complete clinical response, sphincter-preserving operations, organpreserving treatment including low rectal cancer and rate patient compliance with CT.

22 July 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
APA. V. Polynovskiy
A. V. Polynovskiy
ZMZ. Z. Mamedli
Z. Z. Mamedli
DKD. V. Kuzmichev
D. V. Kuzmichev
ATAlexey Tryakin
Alexey Tryakin
OKO. A. Kuznetsova
O. A. Kuznetsova
HTH. R. Temirsultanova
H. R. Temirsultanova
The problem of locally advanced rectal cancer (LARC) treatment has not lost its importance and relevance over the past decades, due to the steady increase in the incidence. For a long time, neoadjuvant chemoradiotherapy (nCRT) before total mesorectal excision (TME) and followed systemic chemotherapy was widely accepted as the standard therapy for locally advanced rectal cancer. Although local control is more than satisfactory using this approach, the same cannot be said of distant metastases, which rate reaches 30 % or more and is mainly the cause of death of this category of patients. One of the reasons for this lack of improvement may be the rate of patients who complete the planned adjuvant chemotherapy, which is approximately 50 %. The reasons for that may be postoperative complications, long-term recovery after extensive surgical procedures, etc. Total Neoadjuvant Therapy (TNT) is an emerging approach for the treatment of LARC aimed at improving distant metastasis. This review will outline the main steps in the evolution of LARC treatment and the formation of the stages of total neoadjuvant therapy.